Haleon (NYSE:HLN) Sees Strong Trading Volume Following Analyst Upgrade

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) saw unusually-high trading volume on Friday after Deutsche Bank Aktiengesellschaft upgraded the stock from a sell rating to a hold rating. Approximately 15,343,841 shares traded hands during trading, an increase of 38% from the average daily volume of 11,082,158 shares. The stock last traded at $8.7460 and had previously closed at $8.57.

Several other research analysts have also recently weighed in on the stock. Royal Bank Of Canada reissued a “sector perform” rating on shares of Haleon in a report on Tuesday, August 11th. Zacks Research downgraded shares of Haleon from a “hold” rating to a “strong sell” rating in a report on Thursday, October 22nd. Berenberg Bank restated a “buy” rating on shares of Haleon in a report on Wednesday, August 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research report on Friday, September 25th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research note on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $4.90.

Haleon News Summary

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon announced a £500 million share buyback, which could provide support for the stock by reducing the number of shares outstanding and signaling management’s confidence in the company’s long-term value. Haleon Cuts 2026 Organic Revenue Growth Forecast and Announces Share Buyback
• Positive Sentiment: Deutsche Bank upgraded Haleon from “sell” to “hold,” reducing some of the negative analyst pressure on the shares. However, the change is not a bullish “buy” recommendation and indicates a more cautious rather than optimistic outlook. Deutsche Bank Haleon Rating
• Neutral Sentiment: The third-quarter sales and trading call provided additional detail on the company’s performance and outlook, with investors focused on slowing growth, pricing and consumer demand. Haleon Q3 2026 Sales and Trading Call Transcript
• Negative Sentiment: Haleon cut its 2026 organic revenue growth forecast to 2.5% after a sales miss. The downgrade raises concerns about weaker demand and makes it more difficult for the company to meet growth expectations. Haleon Cuts 2026 Organic Revenue Growth Forecast
• Negative Sentiment: CEO communications reportedly warned employees that “difficult choices” are ahead following the sales shortfall, suggesting potential cost-cutting or restructuring. The coverage reinforces investor concerns about near-term execution and profitability. Haleon CEO Warns of Difficult Choices

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Mondrian Investment Partners LTD acquired a new position in Haleon during the third quarter worth $158,737,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Haleon by 82.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company’s stock worth $146,892,000 after purchasing an additional 6,647,329 shares in the last quarter. Bank of America Corp DE boosted its holdings in Haleon by 17.0% in the first quarter. Bank of America Corp DE now owns 10,934,228 shares of the company’s stock valued at $109,452,000 after purchasing an additional 1,586,230 shares during the period. Bank Julius Baer & Co. Ltd Zurich increased its position in shares of Haleon by 4.9% in the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,701,182 shares of the company’s stock valued at $42,409,000 after purchasing an additional 219,567 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in Haleon by 8.5% during the 1st quarter. Royal Bank of Canada now owns 3,063,916 shares of the company’s stock worth $30,671,000 after buying an additional 238,841 shares during the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Price Performance

The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. The stock has a fifty day moving average of $9.56 and a 200-day moving average of $9.78. The stock has a market capitalization of $38.43 billion, a price-to-earnings ratio of 22.40, a P/E/G ratio of 2.26 and a beta of 0.14.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.